Review of the Current Issues Surrounding Monitoring of the Direct Thrombin Inhibitor Argatroban in the Laboratory
- 4 May 2026
- journal article
- review article
- Published by Wiley in International Journal of Laboratory Hematology
- Vol. 48 (4) , 737-746
Abstract
The direct thrombin inhibitor argatroban is licensed for use in Heparin‐induced thrombocytopenia. Original trial data gave the recommendation of monitoring argatroban by Activated Partial Thromboplastin Time (APTT) stating a therapeutic target range of 1.5–3.0 times baseline APTT and not exceeding 100 s. APTT has limitations due to prolongation arising in factor deficiencies, lupus anticoagulants, liver disease, and high FVIII levels leading to potential overestimation of argatroban. Argatroban has demonstrated a plateau effect on APTT at higher concentrations; additionally, APTT reagents have different sensitivity to argatroban, potentially underestimating or overestimating the argatroban. Anti‐IIa methods have been recommended as a suitable alternative to accurately quantify argatroban levels. However, there is a lack of consensus on what the target therapeutic range should be. This review will demonstrate how argatroban monitoring by APTT may not be the most suitable method to successfully dose argatroban based on the current state of knowledge and recent published guidelines and highlight the benefits of the anti‐IIa methods.Keywords
This publication has 41 references indexed in Scilit:
- Beyond activated partial thromboplastin time: viscoelastic monitoring of argatroban in the critically illBritish Journal of Anaesthesia, 2025
- Ecarin-based coagulation monitoring of argatroban in patients with heparin-induced thrombocytopenia: a prospective observational studyBritish Journal of Anaesthesia, 2025
- Diagnosis and management of heparin-induced thrombocytopeniaAnaesthesia Critical Care & Pain Medicine, 2020
- Argatroban monitoring: aPTT versus chromogenic assayAmerican Journal of Hematology, 2016
- L’argatroban, nouvel antithrombotique pour la thrombopénie induite par l’héparine en chirurgie cardiaque de l’adulte : utilisation en chirurgie cardiaque et en réanimationAnnales Françaises d'Anesthésie et de Réanimation, 2014
- Development of a fast and simple liquid chromatography–tandem mass spectrometry method for the quantitation of argatroban in patient plasma samplesJournal of Chromatography B, 2012
- Results of a consensus meeting on the use of argatroban in patients with heparin-induced thrombocytopenia requiring antithrombotic therapy – A European PerspectiveThrombosis Research, 2012
- Practical Viewpoints on the Diagnosis and Management of Heparin-Induced ThrombocytopeniaSeminars in Thrombosis and Hemostasis, 2011
- Venous limb gangrene and fatal hemorrhage: Adverse consequences of hit “overdiagnosis” in a patient with antiphospholipid syndromeAmerican Journal of Hematology, 2011
- Argatroban Anticoagulation in Patients With Heparin-Induced ThrombocytopeniaArchives of internal medicine (1960), 2003